Christopher S. Kape, Chief Executive Officer of DPC Biosciences Corporation (“DPC” or the “Company”) (TSX VENTURE: DPC.H), announces that DPC is continuing with its application for regulatory approval of its proposed Change of Business (which involves the confirmation of its asset purchase agreement concerning certain assets which are presently being utilized to derive revenues from online gaming related industries, a contemporaneous name change and an equity private placement).
